PDF(Pubmed)
Abstract：
As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.
摘要：
和其他欧洲国家一样,法国正在经历百日咳在2024年的复苏。在2024年1月1日至5月31日之间，鉴定出5,616（24.9％）百日咳博德特氏菌qPCR检测阳性，在3年的几乎零发病率之后。在67株培养和全基因组测序的百日咳杆菌分离株中，与COVID-19年前相比，66人产生了百日咳杆菌素，56人产生了FIM2。基因型Bp-AgST4的一种分离株对大环内酯类药物具有抗性。百日咳复苏可能有利于产生FIM2和百日咳杆菌素的分离株。
